4D Molecular Therapeutics, Inc.: Novo Holdings A/S amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
Novo Holdings A/S amended its Schedule 13G stake filing for 4D Molecular Therapeutics, Inc., disclosing the change in an SEC filing under accession number 0001388325-26-000053. The amendment updates the Danish investor's reported position in the clinical-stage gene therapy developer, though the filing summary did not specify the revised share count or percentage. Schedule 13G amendments are typically filed by passive investors when their ownership crosses or adjusts around the 5% threshold, making the disclosure a signal of institutional conviction in the small-cap biotech. Investors will watch for the full filing details to see whether Novo added to or trimmed its stake, and for any subsequent 13F or Form 4 disclosures that clarify the direction of the position.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
Novo Holdings A/S, 4D Molecular Therapeutics, Inc.